Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RAD52 | P43351 | 1/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30309430 | 1.00 | LMNA (0.60) | LMNATP53ALOX15TSHRKMT2A | |
| SCHEMBL34473446 | 0.96 | HSP90AA1 (0.56) | LMNATP53ALOX15TSHRKMT2A | |
| SCHEMBL22405367 | 0.86 | P2RX7 (0.45) | LMNATP53ALOX15TSHRKMT2A | |
| SCHEMBL3426843 | 0.86 | HPGD (0.55) | TSHRKMT2AHSP90AA1KDM4EPOLB | |
| SCHEMBL2950806 | 0.84 | HPGD (0.58) | LMNATSHRKMT2AHSP90AA1KDM4E | |
| SCHEMBL3826882 | 0.84 | HPGD (0.58) | LMNATSHRKMT2AHSP90AA1KDM4E | |
| SCHEMBL1156444 | 0.84 | LMNA (0.77) | LMNATP53ALOX15TSHRKMT2A | |
| SCHEMBL2306539 | 0.84 | HRH4 (0.55) | LMNATP53ALOX15TSHRKMT2A | |
| SCHEMBL30309520 | 0.84 | ALDH1A1 (0.49) | LMNAKMT2AHRH4MAPTP2RX7 | |
| SCHEMBL4935992 | 0.84 | ALDH1A1 (0.49) | LMNAKMT2AHRH4MAPTP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317758-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-09-26 | — | — | US | disclosed |
| EP-4320127-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| WO-2022216680-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2020135507-A1 | POLYSUBSTITUTED ANILINOPYRIMIDINE DERIVATIVE AND PREPARATION METHOD AND APPLICATION THEREOF | 杭州百新生物医药科技有限公司 | 2020-07-02 | — | — | WO | disclosed |
| EP-2421846-B1 | 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INT (DE) | 2016-01-06 | — | — | EP | disclosed |
| US-20130281429-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| US-20130281429-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| US-20130281429-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| EP-1948659-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-07-30 | — | — | EP | disclosed |
| CN-101213179-A | 2, 4-diamino-pyrimidines as Aurora inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2008-07-02 | — | — | CN | disclosed |
| EP-1902037-A1 | 2,4-DIAMINO-PYRIMIDINES USED AS AURORA INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007042299-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007042299-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
| US-20070032514-A1 | 2,4-diamino-pyrimidines as aurora inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032514-A1 | 2,4-diamino-pyrimidines as aurora inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032514-A1 | 2,4-diamino-pyrimidines as aurora inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | US | disclosed |
| WO-2007003596-A1 | 2,4-DIAMINO-PYRIMIDINES USED AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007003596-A1 | 2,4-DIAMINO-PYRIMIDINES USED AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | LMNA 334/4885TP53 1167/4885ALOX15 3378/4885 |
| US-20070032514-A1 | 2,4-diamino-pyrimidines as aurora inhibitors | AURKA, AURKC, AURKB | LMNA 1687/4885TP53 94/4885ALOX15 4705/4885 |
| US-20240317758-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | LMNA 196/4885TP53 1525/4885ALOX15 2968/4885 |
| US-20130281429-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | AURKA, AURKC, AURKB | LMNA 1687/4885TP53 94/4885ALOX15 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.